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Surveillance of pregnancies in women living with HIV is carried out on a national basis in 
the United Kingdom (UK) through the National Study of HIV in Pregnancy and Childhood. 
There are currently around 1100–1200 HIV-exposed uninfected (HEU) infants born every 
year in the UK, where vertical transmission of HIV now occurs in fewer than 5 in every 
1000 pregnancies. By the end of 2014, there was a cumulative total of more than 15,000 
HEU children with any combination antiretroviral therapy (cART) exposure and more than 
5000 with cART exposure from conception in the UK. HEU infants are increasingly being 
exposed to newer antiretroviral drugs for which less is known regarding both short- and 
long-term safety. In this commentary, we describe the approaches that have been taken 
to explore health outcomes in HEU children born in the UK. This includes the Children 
exposed to AntiRetroviral Therapy (CHART) Study, which was a consented follow-up 
study carried out in 2002–2005 of HEU children born in 1996–2004. The CHART Study 
showed that 4% of HEU children enrolled had a major health or development problem 
in early childhood; this was within expected UK norms, but the study was limited by 
small numbers and short-term follow-up. However, the problems with recruitment and 
retention that were encountered within the CHART Study demonstrated that compre-
hensive, clinic-based follow-up was not a feasible approach for long-term assessment 
of HEU children in the UK. We describe an alternative approach developed to monitor 
some aspects of their long-term health, involving the “flagging” of HEU infants for death 
and cancer registration with the UK Office for National Statistics. Some of the ethical 
concerns regarding investigation of long-term outcomes of in utero and perinatal expo-
sure to antiretrovirals, including those relating to consent and confidentiality, are also 
discussed.
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Hiv ePiDeMiOLOGY iN THe UK
There were around 104,000 people living with HIV in the UK in 2014, with an overall prevalence of 
1.9 per 1000 people aged 15 years or older, based on multi-parameter evidence synthesis modeling 
conducted by Public Health England (1). Approximately five in six people living with HIV are aware 
of their diagnosis, and around 82% have been linked to HIV care. With respect to women, there 
were an estimated 34,400 women living with HIV in the UK in 2014, with a prevalence of 1.7 per 
1000 among women aged 15–44  years. Among people with diagnosed HIV, 91% were receiving 
2Thorne and Tookey HEU Children in the UK
Frontiers in Immunology | www.frontiersin.org May 2016 | Volume 7 | Article 185
antiretroviral therapy (ART) overall, although this figure was 74% 
in young adults aged 16–24 (1).
SURveiLLANCe OF Hiv iN PReGNANT 
wOMeN AND THeiR CHiLDReN
Surveillance of pregnancies in women living with HIV is car-
ried out in the United Kingdom (UK) and Ireland through the 
National Study of HIV in Pregnancy and Childhood (NSHPC) 
(www.ucl.ac.uk/nshpc). The NSHPC has continuously monitored 
HIV infection in pregnant women and children in the UK and 
Ireland since the late 1980s, and uses two population-based, 
active surveillance reporting schemes, one obstetric and the other 
pediatric. These allow comprehensive coverage of all pregnancies 
to HIV-positive pregnant women living in the UK or Ireland, all 
infants born to HIV-positive women, and all children living with 
HIV infection (2).
Within the obstetric scheme, a named respondent in every 
maternity unit in the UK and Ireland is responsible for notifying 
all pregnancies in HIV-positive women, regardless of timing 
of diagnosis. For each reported pregnancy, demographic and 
clinical information is obtained at notification, with outcomes 
subsequently collected using standardized forms. The pediatric 
reporting scheme involves monthly notification of HIV-
exposed and infected children through the British Paediatric 
Surveillance Unit of the Royal College of Paediatrics and Child 
Health; pediatric units seeing large numbers of HIV-exposed 
children report directly to the NSHPC. Following the initial 
report, a follow-up form is sent to obtain the HIV status of 
exposed children. These active schemes have close monitoring 
and follow-up of non-response to ensure high reporting rates. 
Infants born in the UK or Ireland to women living with HIV 
should be independently reported via both schemes; based on 
data for 2000–2010, over 90% of infants were reported through 
both schemes.
No names are requested or recorded. Respondents provide 
data on demographic characteristics, laboratory results, mater-
nal concurrent infections, ART use, obstetric management, and 
perinatal outcomes. Obstetric and pediatric reports are linked 
by date of birth, geographic location of report, National Health 
Service (NHS) number (a unique identifier), and other demo-
graphic variables. Consent is not required for case notification 
to the NSHPC, and surveillance is exclusively via health-care 
providers. To date, over 19,000 pregnancies to women living 
with HIV in the UK have been reported, with a further nearly 
2000 from Ireland. This paper concentrates mainly on the UK 
data and situation.
eXPOSURe OF iNFANTS TO 
ANTiReTROviRALS iN PReGNANCY  
AND/OR eARLY LiFe
Routine antenatal HIV testing was introduced throughout the UK 
and Ireland from 1999 onward and screening uptake in England 
has exceeded 97% since 2011 (3). In 2014, more than 690,000 
pregnant women in England were tested, with 1.5 women per 
1000 testing HIV-positive (1). Mother-to-child transmission rates 
have been lower than 1% for several years, and in 2010–2011, the 
rate was 0.46% (95% confidence interval: 0.21–0.86%) (2). There 
are currently around 1100–1200 HIV-exposed uninfected (HEU) 
infants born every year in the UK, with a further 80–100 born in 
Ireland. By the end of 2014, there was a cumulative total of more 
than 15,000 HEU children with any combination antiretroviral 
therapy (cART) exposure and more than 5000 with cART expo-
sure from conception in the UK.
In a recent analysis of nearly 6000 pregnancies delivered in 
2009–2014, for 51%, the mother was on ART at conception, in 
28%, she was diagnosed but not on ART, and in 21%, she was 
diagnosed with HIV for the first time during pregnancy (4). 
Overall, 98% of pregnancies were exposed to cART, with a further 
1% exposed to monotherapy. Of the pregnancies in which cART 
was initiated during this time period, a significant trend toward 
earlier start was apparent, with the median gestation at initiation 
shifting from 22  weeks gestation in 2009–2011 to 20  weeks in 
2012–2014.
HIV-exposed uninfected infants are increasingly being 
exposed to newer antiretroviral drugs for which less is known 
regarding both short- and long-term safety (5–8). Although the 
benefits of cART for maternal health and prevention of MTCT are 
profound, it is recognized that there is a need for continued sur-
veillance of the safety of the use of in pregnancy, particularly any 
potential late effects (7, 8). Health differences in HEU children 
compared to unexposed children are increasingly being reported, 
including metabolic, mitochondrial, growth, endocrinological, 
immune, and hematological differences. The potential reasons 
behind these are likely to be complex and inter-related, and may 
include effects of in utero exposures (maternal HIV, ART, other 
medication, or illicit drugs), an altered microbiome, growing up 
in an HIV-affected family, or other factors (5–12).
APPROACHeS TO LONG-TeRM  
FOLLOw-UP OF HeU CHiLDReN iN THe UK
The Children exposed to Antiretroviral 
Therapy Study
The Children exposed to AntiRetroviral Therapy (CHART) 
Study, conducted between 2002 and 2005, was designed to 
investigate the feasibility of establishing a national, clinic-based 
follow-up of HEU children with ART exposure (13). This study 
was designed to sit alongside the core surveillance schemes of 
the NSHPC, which provided information on HEU children 
eligible for enrollment (i.e., those born between 1996 and 
2000). Recruitment was initially restricted to seven hospitals in 
London and four hospitals elsewhere in England with known 
large populations of HEU children; between 2003 and the 2005 
(study’s close), recruitment was expanded to all hospitals with 
deliveries of HEU infants. Pediatric respondents within the 
NSHPC were requested to approach the families of eligible 
children to seek consent for participation, or to contact an alter-
native health-care professional to do so if this was considered 
more appropriate. Data collection consisted of a questionnaire 
to be completed by the health-care professional annually, in 
FiGURe 1 | Flowchart providing enrollment in CHART Study and reasons for non-enrollment. *Paediatric respondent in the NSHPC.
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consultation with the parent/carer of the child; this included 
items on height, weight, hospital admissions, specialist referrals, 
ongoing medication, developmental problems (speech, hearing, 
sight, behavior, and mobility), and any serious health problems. 
This information was then linked to the records held within the 
NSHPC on ART exposure, demographics, perinatal details, and 
laboratory investigations.
Of around 2100 HEU children eligible for enrollment, only 
34% had been enrolled by the end of the study (Figure  1). 
The most common reasons for non-enrollment were formal 
decline of the pediatric respondent to participate, with the 
main reason given being lack of clinic resources, or non-
response of respondents who had not formally indicated 
non-participation. Of note, among the children whose parents 
or carers were approached to invite to participate, the decline 
rate was 12% (100/804). Comparison of the enrolled with 
the unenrolled groups of children showed that there were no 
significant differences with respect to maternal region of birth, 
maternal HIV risk factor, in utero ART exposure, or preterm 
delivery, although enrolled children were born to slightly older 
mothers.
Of the study population of 704 children, a quarter were lost 
to follow-up following enrollment and 2% withdrew from the 
study. This, combined with the slow accrual of HEU children 
to the study, meant that by the end of the study there was only 
repeated follow-up data on a quarter of children, with most just 
having data available at a single time point. Nearly all of the 
enrolled children had been exposed to ART in utero, with 70% 
exposed to cART. The median age at CHART assessment was 
24 months. Overall, 63% (440/704) of the children had at least 
one health or developmental problem reported, the majority 
of which were common childhood infections or conditions. 
The main groups of conditions were colds/chest infections (in 
201 children); wheezing/asthma, eczema, or other allergies (93 
children); speech delay or problems (50 children); gastroenteri-
tis (28 children); and febrile seizures (11 children). A further 
63 children had other minor developmental or behavioral 
problems. There were significant health problems or conditions 
reported in 27 (4%) children of whom 93% were ART-exposed; 
5 had with sickle cell anemia, 3 had cerebral palsy (all preterm), 
3 had autistic spectrum disorder, 1 had traumatic head injury, 
and the remainder had various congenital defects. For the 
enrolled children as a whole, 9% had been admitted to hospital 
at least once.
Although comparison of maternal characteristics of the 
enrolled with the non-enrolled children was reassuring, with no 
significant difference with respect to specific maternal/exposure 
characteristics, the low enrollment rate precluded any firm 
conclusions on the safety of ART exposure in HEU children. 
Furthermore, follow-up time was short, and only a quarter of the 
children had repeat questionnaires available. Most of the signifi-
cant health problems identified were congenital abnormalities, 
on which data are already routinely collected in the NSHPC. The 
prevalence rates of common conditions in the enrolled children 
were compared with those reported for the UK Millenium Cohort 
Study (MCS), which oversampled children from disadvantaged 
and minority ethnic wards (14), and the observed rates were in 
the range reported for the MCS.
The CHART Study demonstrated the challenges in conduct-
ing a follow-up study of HEU children, with key barriers being 
lack of capacity at pediatric clinics and family mobility. It was 
concluded that consented, clinic-based follow-up would not be 
a feasible approach for monitoring outcomes in ART-exposed 
HEU children in the UK.
TABLe 1 | Four follow-up options for HeU children explored in surveys of parents/carers and health-care professionals.
Option Description
Clinic contact Annual follow-up visit at pediatric clinic with data (no names) sent to the NSHPC. Parents/carers would need to inform the clinic of 
contact detail changes
Telephone contact Pediatric clinic staff would call parent/carer annually to collect brief information about the child’s general health. Responses entered 
on a form and sent to NSHPC (no names). Parents/carers would need to inform the clinic of contact detail changes
Postal contact NSHPC would be provided with contact details of parent/carer by the clinic when the child was discharged from routine care. A 
short form on the child’s health would be sent to parent/carer annually for completion and return to NSHPC (no reference to HIV 
anywhere on the form or correspondence). Parents/carers would need to inform the NSHPC of contact detail changes
No direct contact NSHPC uses child’s NHS number to link to routinely available health information. No further contact with clinic or NSHPC needed 
after child is discharged
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Survey of Parents’ and Health-Care 
Providers’ views on Long-Term Follow-up 
of HeU Children
Following the experiences within the CHART Study, there was a 
need to explore alternative approaches to monitoring the health 
of HEU children and, in particular, the acceptability of different 
approaches to parents/carers and to health-care professionals. 
Two surveys were conducted with these two stakeholder groups 
during 2004 and 2005 to assess their views on four different 
strategies for follow-up (Table 1) (15). The parent/carer survey 
was carried out in 12 pediatric clinics and 2 genitourinary 
medicine clinics (8 in London, 1 in Wales, 1 in Scotland, and 4 in 
England), with 140 questionnaires completed, mostly by moth-
ers of HEU children (91%). Nearly all parents/carers agreed with 
the statement “it is important to follow-up uninfected children 
to see if there are any side effects from anti-HIV drugs.” All, 
but one, parent/carer respondents indicated that at least one of 
the four follow-up strategies would be acceptable, and two-fifths 
supported more than one option. The most popular strategy 
was clinic contact (61%). Overall, 23% of respondents strongly 
objected to at least one of the options, with postal contact as 
the option that was most strongly objected to. Eight percent 
of parents/carers strongly objected to the “no direct contact” 
option; for one-third, the reason given was a desire to be seen 
in clinic, with a few giving the reasons of lack of consent (n = 2) 
and not wanting their child “labeled” or on a “register” (n = 2). 
The survey also investigated primary health-care use: 97% of 
respondents took their child to a general practitioner, and in 
81% of cases, the general practitioner was aware of HIV in the 
family. Respondents were asked about contact from health ser-
vices in the scenario of a potential health risk associated with 
exposure to a particular antiretroviral drug being identified: 
84% indicated that they should be informed of such a risk even 
in the absence of a treatment or intervention, 14% that they 
should only be informed where treatment or intervention was 
available, and the remainder did not want to be contacted in 
any circumstance.
The health-care professional survey was smaller, involving 40 
respondents from hospitals across the UK (87% response rate), 
of whom half were pediatricians and 40% pediatric nurses. All 
considered at least one of the options acceptable; acceptability 
of clinic contact, telephone contact, postal contact, and no direct 
contact was 70, 58, 55, and 53%, respectively. Overall, 28% 
strongly objected to clinic and/or telephone contact (where the 
burden of contact lay with the pediatric clinic), with lack of clinic 
resources being the main reason for this objection.
Use of National Routine Data to Monitor 
Death and Cancer in HeU Children in 
england and wales
Synthesis of the results of both the CHART Study and the survey 
provides a complex and sometimes contradictory picture of 
potentially acceptable and feasible approaches for long-term 
monitoring of outcomes in HEU children. Although annual 
clinic-based follow-up was the most acceptable option to par-
ents and carers in the survey, the CHART Study demonstrated 
that this approach failed as a robust and sustainable strategy 
for monitoring health of HEU children. Furthermore, such an 
approach is not practical, or indeed, justifiable for surveillance 
on a population level using NHS resources, particularly when 
considering the cumulative increase in the HEU population. It 
was therefore clear that another approach for long-term surveil-
lance of the health of HEU children was needed, even if this 
only provided data on a limited range of outcomes. The majority 
of parents and carers in the survey had no strong objection to 
the “no direct contact” option, using record linkage to routine 
health data.
A pilot study to “flag” HIV-exposed infants also exposed to 
antiretroviral drugs in fetal life with national registers to obtain 
notifications of any death or cancer registrations had been car-
ried out in the 1990s. However, this process relied on manual 
matching to identify the relevant birth registration records, 
due to limited availability of the unique NHS number within 
the NSHPC at the time, and progress was slow; fewer than 
400 children born between 1996 and 1999 were flagged with 
this system. In 2002, the NHS “Numbers for Babies” initiative 
resulted in the new policy of NHS numbers being allocated at 
birth rather than at civil registration and, as a result, an increas-
ing proportion of infants reported to the NSHPC from this time 
had NHS number reported. To capitalize on this, in 2005, a new 
protocol was established for flagging children born to moth-
ers living with HIV in England and Wales. This was initially 
via the NHS Central Register, administered by the Office of 
National Statistics, but following national restructuring, is now 
conducted via the Health and Social Care Information Center 
(HSCIC) (16).
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An encrypted dataset containing the NSHPC variables, 
 including NSHPC study number and the variables above, is 
securely transferred to HSCIC. The flagging procedure uses a 
matching algorithm, necessary not only because the NSHPC 
does not collect names but also because it is not appropriate 
to rely solely on the NHS number because of the potential for 
transcription errors. Child date of birth, sex, and NHS number 
allow for the large majority of children to be matched to the 
central record, but other variables (maternal date of birth and 
partial postcode of residence at delivery) are required to match 
the remaining children. Infant birthweight may also be used in 
an additional component of the algorithm where matching is 
complicated by twins. The flag within the central record has a 
generic label with no mention of HIV. A pseudonymized listing, 
with NSHPC study number as the sole identifier, is subsequently 
returned to the NSHPC. Events (i.e., deaths or cancer) are noti-
fied to the NSHPC twice a year, and include date and cause of 
death, and year of diagnosis, site, and type of cancer for death and 
cancer registrations, respectively. In an evaluation of the flagging 
procedure conducted on nearly 3000 children born 2001–2004 
in England and Wales, flagging was possible in 95% of cases (16).
Currently, there are about 8000 uninfected infants born in 
England and Wales flagged, 97% born between 2001 and 2009, 
and the remainder earlier. This represents about half of all HEU 
children born in England and Wales to date. The NSHPC is 
currently working on flagging those born more recently and on 
assessing the event notifications.
In terms of monitoring the long-term health of HEU children, 
a drawback of our flagging approach is that death and cancers are 
the only available events, and this does not offer the opportunity 
to explore other morbidities, particularly those that may be 
associated with mitochondrial toxicity. There are possible options 
for additional record linkage studies, for example, with hospital 
episode statistics, in order to investigate whether any clinical out-
comes are associated with in utero exposure to ART and maternal 
HIV. Another approach might be to conduct record linkage with 
results from the national program on newborn screening for 
inborn errors of metabolism, as was recently carried out in New 
York State (17), with the aim of determining whether the pattern 
of metabolic disorders is suggestive of mitochondrial toxicity. 
The feasibility and acceptability of such approaches need to be 
evaluated in the UK setting.
The benefits of our approach include good contemporaneous 
ascertainment of exposure to antiretroviral drugs (although direct 
adherence data are not collected, maternal viral load can be used 
as a proxy marker of adherence) and availability of other maternal 
and perinatal variables from the NSHPC database. There is likely 
to be minimal case ascertainment bias, as death registration is 
mandatory, and English cancer registries have been shown to 
have ascertainment rates of around 98–99% (18).
The ethical and information governance issues around any 
flagging study are important, but particularly in the context 
of fetal exposure to maternal HIV and to antiretroviral drugs, 
where there are concerns regarding disclosure and confidentiality 
within a family as well as in general. The original flagging study 
had independent approval from the relevant national body (the 
Patient Information Advisory Group), but is now a recognized 
component of the NSHPC as a whole, and covered with NSHPC 
ethical approval and approvals for use of non-consented patient 
identifiable data. The flagging process has been assessed as 
acceptable against NHS Information Governance policies and 
standards. Another important issue relates to the communication 
with mothers, fathers, children, and young people regarding safety 
monitoring, in order to reassure rather than provoke anxiety. The 
survey results demonstrate that, unsurprisingly, there was sup-
port from parents with respect to the need for monitoring (15), 
although this survey was conducted more than a decade ago and 
attitudes may have changed in the interim.
As mentioned above, we are currently working on extending 
the flagging to include the most recent birth cohorts of HEU 
children and on updating the previous results (16). No signal 
has yet been identified that raises concern about fetal exposure 
to ART with respect to cancer or death. However, consideration 
needs to be given to the necessary steps should a signal become 
apparent, for example, if rates for a specific cancer or cancer site 
were recorded at a higher rate than in the same age group in the 
general population.
APPROACHeS TO MONiTORiNG 
OUTCOMeS iN HeU CHiLDReN iN  
OTHeR COUNTRieS
The French Perinatal Cohort (ANRS-Enquête Périnatale 
Française, EPF) has also used the approach of record linkage with 
national cancer registers to explore outcomes in HEU children. 
The EPF is a consented cohort study, with HEU children routinely 
followed up until age 2 years, after which there is a spontaneous 
pharmacovigilance reporting system with investigators reporting 
any known severe events (19). As for the NSHPC, the EPF does 
not collect names, and used child date and place of birth and 
sex to identify potential matches on the cancer registries, with 
manual checking. In addition to the registry linkage and sponta-
neous reporting, a specific information campaign was conducted 
to elicit spontaneous notification by a network of pediatric cancer 
specialists. No evidence of an overall increased cancer risk was 
found for HEU children born between 1984 and mid-2007 
(median age, 5 years), using national rates as a reference; 5 of the 
10 cancer cases were central nervous system malignancies, with a 
standardized incidence ratio of 3.1 (95% confidence interval 1.0, 
7.2; p = 0.05).
Unlike the UK, a cohort study approach to monitor the health 
of HEUs has been successfully undertaken in the United States. 
The Pediatric HIV/AIDS Cohort Study (PHACS) Surveillance 
Monitoring of Antiretroviral Toxicity (SMART) protocol was 
established in 2005 and follows two cohorts of HEU children, 
one closed to new enrollments that include over 1200 children 
and the other continuing to enroll HEU infants. The SMART 
study uses a trigger-based approach to explore possible signals, 
whereby more rigorous, pre-defined investigations in individual 
children are prompted if predetermined clinical or laboratory 
thresholds are met, with a recent analysis reassuringly showing no 
association between meeting a case criteria and any antiretroviral 
class, regimen, or individual drug (20).
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CONCLUSiON
The problems with recruitment and retention that were encoun-
tered within the CHART Study demonstrate that comprehensive, 
clinic-based follow-up is not a feasible approach for long-term 
assessment of the increasing number of HEU children in the UK. 
Although this Study was conducted more than 10 years ago, it 
likely that many of these problems would remain an issue today, 
particularly limited capacity at pediatric clinics and family mobil-
ity. It will therefore be important to continue flagging HEU chil-
dren in cancer and death registries as one approach to monitoring 
for specific adverse outcomes of exposure to ART, particularly 
late outcomes that may not become apparent until late childhood, 
adolescence, or adulthood. The experience regarding in  utero 
exposure to diethylstilbestrol (DES) underscores the need for 
long-term surveillance into adulthood, with the substantially 
and significantly elevated risk of rare cervical/vaginal cancers in 
daughters of women taking DES in pregnancy not identified until 
two or more decades after exposure (21–23). Future research 
strategies to address other health outcomes, including adverse 
events potentially related to mitochondrial/metabolic toxicity, in 
HEU children are being discussed, to capitalize on the NSHPC 
as a comprehensive, national surveillance anonymized record 
of HEU infants born to diagnosed women and the current and 
potential availability of electronic health records in the UK for 
record linkage.
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